Paris, FRANCE, October 6th, 2005 - Aureus Pharma, a provider of knowledge management solutions to aid discovery in the life sciences industry, today announces that Euroscreen, SA has become a customer of its AurSCOPE® GPCR knowledge database. Euroscreen joins a growing list of companies using Aureus Pharma's technology, including sanofi-aventis, Roche, and Servier. The financial terms of the agreement were not disclosed.

AurSCOPE GPCR provides researchers rapid access to quantitative biological activity data mined from the scientific journals and patents for all known GPCR's, a major class of membrane proteins. As GPCR's are the target for nearly 50% of all drugs today, this wealth of knowledge is crucial to new drug discovery.  

Euroscreen will use Aureus Pharma's technology in conjunction with their in-house technology to identify new GPCR drug candidates.  "By integrating the Aureus GPCR knowledge database with Euroscreen's research platform, our scientists will be able to rapidly prioritize candidates in lead generation and optimization programs" said Dr. Francois Roman, Vice President R & D for Euroscreen. "The information contained within the database will also help us in the design of our chemical libraries for our screening campaigns" said Dr. Frederic Ooms, Head of Chemistry for Euroscreen

"As Euroscreen is a world leader in GPCR research, we are pleased they have adopted our AurSCOPE GPCR knowledge base" said Dr. Andre Michel, CEO of Aureus Pharma. "AurSCOPE GPCR with its high quality biological and chemical information will complement Euroscreen's technology resulting in an overall acceleration of the discovery process."

About Aureus Pharma

Aureus Pharma headquartered in Paris, France is a privately held knowledge management based solutions provider for the life sciences industry. Aureus Pharma accelerates new drug discovery by providing knowledge databases which contain high quality quantitative information for both chemistry and biology.  Researchers gain rapid access to knowledge for important drug target classes including GPCR, Ion Channel, Kinase as well as other critical pharmaceutical topics including ADME/Drug-Drug Interactions and the hERG Channel.  The information contained in the Aureus Pharma system is of primary importance to aid in lead discovery and optimization as well as to build predictive models. For further information on how Aureus Pharma helps researchers turn data into discovery visit www.aureus-pharma.com

About Euroscreen SA

Euroscreen is a world leader in G-protein coupled receptors . The Company integrates its research expertise in this area with its patented high-throughput AequoScreen™ cellular assay platform to patent new GPCR targets and drug candidates.  The Company is building its own patent portfolio of GPCR targets and novel drug leads for licensing to biopharmaceutical companies, and to date has agreements with Cephalon, CyBio, EvotecOAI, GE Healthcare, ICOS, Merck & Co, Pfizer Inc, Solvay, Syngenta and UCB. Euroscreen is a privately held company based in Brussels, Belgium with 80 employees of which 50 are in R&D.

Contact:
Mary E. Donlan, Ph.D
Director of Marketing & Sales
+33 1 40 18 57 59
mary.donlan@aureus-pharma.com